Clinical Trials Logo

Substance Withdrawal Syndrome clinical trials

View clinical trials related to Substance Withdrawal Syndrome.

Filter by:

NCT ID: NCT03114904 Completed - Withdrawal Syndrome Clinical Trials

Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses

NEUROSEV
Start date: February 27, 2016
Phase: N/A
Study type: Interventional

The withdrawal syndrome in benzodiazepines and morphine is common in intensive care, the incidence is estimated at 32.1%. Cerebrospatized patients are probably more prone to withdrawal because they require high doses of sedation. Moreover, this syndrome is probably deleterious on the cerebral hemodynamics (high point of the therapeutic management).

NCT ID: NCT03077932 Completed - Clinical trials for Opiate Withdrawal Syndrome

An App to Aid in Transitioning Off Opioid Medication

BetterOFF
Start date: April 1, 2016
Phase: N/A
Study type: Interventional

The investigators propose to develop a smartphone app (called BetterOFF) that will help patients manage opioid withdrawal during opioid medication taper and detoxification. The BetterOFF smartphone intervention will be a resource patients can access anytime and anywhere. If the BetterOFF intervention were to be effective in helping patients discontinue opioid medication, it could be integrated into the standard of care of office-based clinical practices, as well as substance use programs, thereby having a substantial public health impact.

NCT ID: NCT03033823 Completed - Clinical trials for Alcohol Withdrawal Syndrome

MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)

MAGMA
Start date: November 16, 2017
Phase: Phase 3
Study type: Interventional

This study examine the efficacy of oral magnesium supplementation as an adjuvant therapy for decreasing intensity of alcohol withdrawal symptoms among inpatients requiring pharmacological treatment of their AWS. This double blind randomized multicenter clinical trial planned to treat half of participants as usal plus placebo and the other half as usual plus magnesium.

NCT ID: NCT03018977 Completed - Withdrawal Syndrome Clinical Trials

Protocolized Sedative Weaning VS. Usual Care in Pediatric Critically Ill, RCT

Start date: January 2017
Phase: N/A
Study type: Interventional

Sedative and analgesic agents are widely used in the ICU. These agents can provide hypnotic effect, pain alleviation, cooperation, and synchronizing ventilatory support. Prolonged use of the agents can lead to withdrawal symptoms when the drugs are weaned. Prior study showed the longer duration of sedative drugs, cumulative dose of medications and younger age were the risk factors of withdrawal syndrome. Additional, some study showed the sedation protocol can reduce the incidence of withdrawal syndrome. However, no worldwide standardized sedative weaning protocol including our hospital. The objectives in this study are to establish the sedative weaning protocol and to compare the protocol sedative weaning with the usual care weaning.

NCT ID: NCT03017430 Completed - Opioid Withdrawal Clinical Trials

Pregabalin for Opiate Withdrawal Syndrome

Start date: January 2014
Phase: Phase 4
Study type: Interventional

It is a single blind randomized symptom triggered study to assess efficacy and safety of pregablin combined with the symptom triggered treatment for opiate withdrawal syndrome vs. clonidne with the same with the symptom triggered treatment for opiate withdrawal syndrome.

NCT ID: NCT03012815 Completed - Clinical trials for Alcohol Withdrawal Syndrome

Gabapentin for Alcohol Withdrawal Syndrome

Start date: February 1, 2017
Phase: Phase 4
Study type: Interventional

The current "gold-standard" for the management of alcohol withdrawal syndrome (AWS) is symptom-triggered administration of benzodiazepines. This method of treatment has several drawbacks that have been described in the literature. Thus benzodiazepine sparing agents have been evaluated for use in AWS. One of these agents that has not only shown benefit for AWS but also benefits on complete abstinence, reducing a return to heavy drinking, and cravings is gabapentin. In clinical practice at Mayo Clinic gabapentin is used for this purpose. Due to the limited reports of the safety and efficacy of a protocol involving gabapentin for AWS, a study to compare gabapentin to symptom-triggered lorazepam will be completed.

NCT ID: NCT03012373 Enrolling by invitation - Clinical trials for Opiate Withdrawal Syndrome

Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts

AAMTH
Start date: June 2016
Phase: N/A
Study type: Interventional

This is an open-label, randomized, 2-sequence, cross-over study evaluating the difference of efficacy between ear acupressure alone and ear acupressure plus electroacupuncture therapy both combined with methadone treatment services for heroin addicts.

NCT ID: NCT02952846 Completed - Child Clinical Trials

Tapering of Analgosedation and Occurrence of Withdrawal Syndrome in Paediatric Intensive Care Treatment

ASWISPIC
Start date: May 2016
Phase: N/A
Study type: Interventional

The study is a prospective interventional study with three main aims: 1. Describe the frequency and severity of withdrawal syndrome in a population of paediatric intensive care patients. 2. Test whether implementation of an algorithm for tapering of analgosedation changes the frequency and severity of withdrawal symptoms in the same population. 3. Investigate how the health care providers experience having to adhere to such an algorithm.

NCT ID: NCT02951793 Active, not recruiting - Clinical trials for Substance Withdrawal Syndrome

Abuse and Addiction in ICU

Start date: March 2016
Phase:
Study type: Observational

Investigators are seeking to determine the impact of recent alcohol, smoking or psychotropic drug use prior to intensive care unit (ICU) admission on incidence of delirium and sedation requirements. Study design: A prospective observational study, in a medical ICU of a tertiary university hospital. Methods: For all new ICU admissions, a 1-page questionnaire including Alcohol Use Disorders Identification Test (AUDIT-C), smoking history and prior medication use was given to the patient or closest family members. Delirium was assessed by trained ICU nurses using Intensive Care Delirium Screening Checklist and Richmond Agitation-Sedation Scale.

NCT ID: NCT02916628 Terminated - Smoking Clinical Trials

Effects of Auricular Acupressure and Group Counseling on Smoking Cessation Tobacco Withdrawal Symptoms

Start date: July 2013
Phase: N/A
Study type: Interventional

Objective The purpose of this study is to examine the effects of auricular acupressure and group counseling with positive psychology and motivational interviewing on smoking cessation and tobacco withdrawal symptoms. Methods This study is a single blind randomized controlled trial. This study has been performed at a University in South Korea. 180 smokers and 60 non-smokers will be recruited. Smokers will be randomly assigned to three groups: group 1 (auricular acupressure + group counseling); group 2 (placebo acupressure + group counseling); and the control group (self-help smoking cessation). Group counseling is undertaken once per week for 6 weeks. Auricular acupressure using acupellets is performed for 6 weeks continuously.